Targeting angiogenesis as a promising modality for the treatment of prostate cancer.
Antiangiogenic therapy has been successful for the treatment of solid tumors. Several strategies have been used to target angiogenesis in prostate cancer. These strategies include blocking proangiogenic factors via monoclonal antibodies or small molecule inhibitors targeting downstream signaling effector pathways, or using agents with immune-modulatory effects. This review examines the general concepts of tumor angiogenesis and the key clinical trials that have used these agents and other novel biologics in prostate cancer. Targeting angiogenesis is still a promising treatment strategy in prostate cancer with a rational trial design and combination approach.
Department of Medical Oncology, Jefferson Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA. Jianqing.lin@jefferson.edu
Jianqing
J
Lin
William K
WK
Kelly
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000813:Anilides / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D000068258:Bevacizumab; D018450:Disease Progression; D004359:Drug Therapy, Combination; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D000077210:Sunitinib; D013792:Thalidomide / Q000009:adverse effects; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000813:Anilides; D061067:Antibodies, Monoclonal, Humanized; D007211:Indoles; D011725:Pyridines; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; C558660:cabozantinib; D000068258:Bevacizumab; D013792:Thalidomide; D000077210:Sunitinib